Biohaven Pharmaceutical (BHVN) Stock Forecast, Price & News

Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Biohaven Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHVN, but not buy additional shares or sell existing shares.
View analyst ratings for Biohaven Pharmaceutical or view top-rated stocks.

Are investors shorting Biohaven Pharmaceutical?

Biohaven Pharmaceutical saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 4,130,000 shares, a drop of 16.2% from the April 30th total of 4,930,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 2.7 days. Approximately 6.7% of the company's stock are short sold.
View Biohaven Pharmaceutical's Short Interest.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Biohaven Pharmaceutical.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) issued its earnings results on Tuesday, May, 10th. The company reported ($2.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.45. During the same quarter in the previous year, the firm earned ($4.21) EPS.
View Biohaven Pharmaceutical's earnings history.

What price target have analysts set for BHVN?

8 equities research analysts have issued twelve-month target prices for Biohaven Pharmaceutical's stock. Their forecasts range from $130.00 to $177.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $155.11 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:

• Dr. Vladimir Coric M.D., Chairman, CEO & Pres (Age 51, Pay $1.81M)
• Mr. Matthew Buten, Chief Financial Officer (Age 61, Pay $766.47k)
• Ms. Kimberly Gentile, Sr. VP of Clinical Operations (Age 56, Pay $1.03M) (LinkedIn Profile)
• Dr. Elyse Stock M.D., Chief Medical Officer (Age 63, Pay $1.15M)
• Mr. William Jones M.B.A., Chief Commercial Officer of Migraine & Common Diseases (Age 58, Pay $1.04M)
• Mr. Matthew DeLawder, Director of Accounting
• Mr. George C. Clark, VP & Chief Accounting Officer (Age 38) (LinkedIn Profile)
• Dr. Charles Conway Ph.D., Chief Scientific Officer (Age 60)
• Ms. Wendy Goss, Exec. Admin. Assistant
• Mr. Clifford Bechtold M.S., Pres & GM of Biohaven Ireland and Chief Compliance Officer

Who are some of Biohaven Pharmaceutical's key competitors?

Some companies that are related to Biohaven Pharmaceutical include Astellas Pharma (ALPMY), Royalty Pharma (RPRX), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Horizon Therapeutics Public (HZNP), Genmab A/S (GMAB), Genmab A/S (GNMSF), Catalent (CTLT), UCB (UCBJF), Shiseido (SSDOY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Ono Pharmaceutical (OPHLF) and BeiGene (BGNE).
View all of BHVN's competitors.

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital World Investors (9.42%), BlackRock Inc. (6.60%), Capital International Investors (3.80%), State Street Corp (2.35%), Vanguard Group Inc. (2.02%) and JPMorgan Chase & Co. (1.94%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Gilder Gagnon Howe & Co. LLC, Invesco Ltd., Hood River Capital Management LLC, EULAV Asset Management, Northern Trust Corp, Nicholas Investment Partners LP, and Pier Capital LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, George C Clark, James Engelhart, and Julia P Gregory.
View insider buying and selling activity for Biohaven Pharmaceutical or view top insider-selling stocks.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, American Century Companies Inc., Capital World Investors, Eversept Partners LP, Clearbridge Investments LLC, Fairmount Funds Management LLC, Lord Abbett & CO. LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Biohaven Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $143.37.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $10.11 billion and generates $462.51 million in revenue each year. The company earns $-846.59 million in net income (profit) each year or ($11.840010) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 928 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 404-0410 or via email at [email protected].